Review
Open access
Sep 2026
Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia
KarXT (marketed as Cobenfy™), a fixed-dose combination of xanomeline and trospium chloride, represents the first new mechanism of action of an antipsychotic used for adult schizophrenia approved by the US Food and Drug Administration (FDA) in over 30 years. While mainstream drugs (e.g. haloperidol, chlorpromazine, risp...
Izabela Żuraw, Krystian Urbański, Patryk Kogut et al.
· Frontiers in Psychiatry · 0 citations